TMCnet News

Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
[September 09, 2021]

Enlivex to Present at the H.C. Wainwright 23rd Annual Global Investment Conference


Nes-Ziona, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that Company management will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.

The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, September 13, 2021 and can be accessed through the following link: https://journey.ct.events/view/05f06487-cd1d-4dbb-8088-fb6559861045.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherap company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information visit http://www.enlivex.com



ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com


INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com


Primary Logo


[ Back To TMCnet.com's Homepage ]